Introduction {#S1}
============

Huntington's disease (HD) is a genetic neurodegenerative disease caused by expanded CAG triplet repeats in the first exon of *HTT* gene ([@B38]). A biological hallmark of HD is the formation of intracellular insoluble protein aggregates (inclusions) found in the brains of affected patients ([@B16]; [@B9]; [@B23]). *In vivo* and *in vitro* studies in the past two decades confirmed that these aggregates are composed of mutant Huntingtin (mHtt) alone or together with other proteins \[reviewed in [@B5] and [@B30]\]. This is partially because the expanded CAG repeats in mutated *HTT* translate to an expanded polyglutamine (polyQ) sequence in mHtt and makes it prone to misfolding and aggregating ([@B57], [@B58]). Whether these aggregates found in HD patients are toxic, benign or even protective, however, has been long debated. On the one hand, the correlation between polyQ length, aggregation appearance and HD age-of-onset indicates potential toxicity of mHtt aggregates ([@B15]; [@B45]; [@B9]; [@B49]). On the other hand, the formation of mHtt aggregates has also been reported to be separable from cell death and might even be beneficial for cell survival ([@B56]; [@B31]; [@B6]).

While the debate goes on, the field's understanding of mHtt aggregation and toxicity, nonetheless, has been evolving as well. It is now known that mHtt proteins exist in the forms of monomers, soluble oligomers, and insoluble polymers both *in vivo* and *in vitro*. The formation of mHtt oligomers and polymers from monomers is polyQ length- and time-dependent, likely in a monomer→oligomer→polymer order ([@B52]; [@B27]; [@B62]; [@B34]; [@B37]; [@B44]; [@B39]; [@B32]). mHtt species of similar sizes can manifest conformational polymorphism. For monomers and oligomers, mHtt species recognized by the monoclonal antibody 3B5H10 shows higher neurotoxicity than the others ([@B41]; [@B51]). Structural biology indicates these 3B5H10-recognized mHtt species adopt a more compact conformation. A later work found that they are resistant to selective autophagy and thus have a lower degradation rate ([@B19]). Whether this is directly linked to their compact structure is not yet clear. Interestingly, the insoluble mHtt polymers/aggregates also have diverse conformations. A study using synchrotron-based infrared microspectroscopy revealed that mHtt aggregates from adult and juvenile HD patients' brains display three conformations (non-amyloid, amyloid with β-sheet/unordered, and amyloid exclusively with β-sheet), among which the amyloid with β-sheet/unordered structures is distributed positively correlated with brain regions affected by HD ([@B4]). Another study in immortalized mouse striatal STHdhQ7/Q7 cells found that overexpressed mutant huntingtin fragments can form two types of inclusions, the tightly packed fibrillar inclusion and the loosely packed globular inclusion, based on their morphological appearance under super-resolution microscopy and fluorescence lifetime imaging microscopy (FLIM)-Förster resonance energy transfer (FRET) ([@B14]). The authors also found that these two types of inclusions have different dynamic properties, in that the fibrillar inclusion does not exchange protein with the soluble phase while the globular inclusion does. Similarly, a later study using an Htt exon1 biosensor that can distinguish protein structures based on their accessibility to biarsenical dyes revealed that mHtt exon1 product (mHtt~ex1~) forms disordered inclusions early and then convert to β-sheet-rich amyloid over time ([@B54]). Taken together, accumulating evidence indicates that mHtt forms conformationally distinct monomers, polymers and inclusions ([@B38]); mHtt species with certain conformation(s) are more toxic than the others ([@B16]); different mHtt conformations may convert from one to another ([@B9]). The mechanism(s) underlying their formation and possible conversion, however, is still largely unknown.

Very recently, several studies carried out *in vitro* in yeast and mammalian cells indicated that the formation of mHtt assemblies is mediated by phase separation and phase transition ([@B50]; [@B53]; [@B1]). These findings suggested the involvement of a new mechanism in the formation of mHtt aggregates and thus provided new clues to understand their polymorphism in conformation and toxicity. We will summarize these works and discuss their possible pathological relevance in the following sections.

Phase Transition in Cells {#S2}
=========================

The term "phase" in physics is used to describe a thermodynamic system composed of materials with uniform physical properties. The change from one phase to another is coined phase transition (e.g., a transition from liquid phase to solid phase). Liquid--liquid phase separation (LLPS) is a special kind of phase transition that refers to the separation of a solution into two distinct co-existing phases, whereas one is solute-enriched and the other is solute-absent ([@B2]) (also see [Figure 1](#F1){ref-type="fig"}). Although the idea that cytoplasm to be a mixture of liquid with suspending droplets of different chemical properties can be tracked back to as early as 1899 ([@B65]), the intracellular phase separation was not experimentally demonstrated until [@B11] found that the P granule is liquid-like and formed by LLPS. The same group also revealed that nucleoli also have liquid-like behavior ([@B12]). During the past decade, the intracellular phase separation of more biological macromolecules has been discovered, suggesting that phase separation might be a common mechanism for cells to regulate essential biological processes \[reviewed in [@B2], [@B22], [@B59], [@B10]\]. In line with this notion, aberrant phase separation is proposed to contribute to the pathology of diseases ([@B26]; [@B13]; [@B63]).

![Liquid-liquid phase separation. A schematic chart of liquid-liquid phase separation (LLPS). In a solution composed of evenly distributed solute molecules (the green bubbles) and solvent molecules (gray bubbles), when LLPS occurs, the solute molecules condense to form a membraneless liquid-like phase and leaves a surrounding region absent of the solute molecules.](fgene-11-00754-g001){#F1}

Phase Transition of mHtt {#S3}
========================

mHtt Forms Different Phases and Undergoes Phase Transition {#S3.SS1}
----------------------------------------------------------

A few recent studies indicate that mHtt undergoes phase transition to form higher-ordered assemblies, both *in vitro* and in cells.

Using a combination of solubility analysis, right-angle static light scattering and transmission electron microscopy, [@B53] reported that purified huntingtin N-terminal fragments (Htt-NTF) formed three phases distinguished by their saturation concentration, size, and shape. More specifically, the authors designated them as the M phase (consists of soluble monomers and oligomers), the S phase (mainly consists of bigger soluble aggregate spheres sized about 25 nm in diameter), and the F phase (mainly consists of insoluble fibrillar aggregates). Htt-NTF can separate into different phases when its concentration goes above a construct-specific saturation concentration.

In another study published in 2018, [@B50] used correlative light and electron microscopy (CLEM) and time-lapse fluorescence microscopy to study the aggregation of Htt~ex1~-GFP proteins. They observed that Htt~ex1~-GFP forms dim liquid-like and bright solid-like assemblies, *in vitro*, in yeast cells as well as in mammalian cells. More interestingly, the authors also found that the liquid-like Htt~ex1~-GFP assemblies are formed by LLPS and can convert into solid-like assemblies by phase transition.

[@B1] reported that in yeast cells, mHttex1-GFP form bright membrane-less spherical phase-separated inclusion bodies (IBs) with uniform GFP intensity. However, based on the timescale in FRAP experiments, the authors concluded that the nature of IBs they observed are not "fully liquid" nor solid but rather gel-like. Besides the IBs, the authors also observed clusters of smaller inclusions (which they named cluster like inclusions or CLIs) that are asymmetrical in shape and GFP intensity, in a small proportion of cells. Moreover, the authors also tracked the random movements of small mHtt~ex1~-GFP particles and propose that their collision and coalescence lead to the development of mHtt inclusions.

Taken together, the above-mentioned studies all indicated that Htt~ex1~ manifest phase transition, supported by evidence from thermo-kinetics, light scattering, quantitative fluorescent microscopy, and electron microscopy experiments. However, besides the common findings pointing to mHtt phase transition, these studies used quite different methodology and focused on different aspects of mHtt phase behavior (see [Table 1](#T1){ref-type="table"} for summary). For instance, [@B53] studied sub-micron-sized Htt species and factors that affect their thermo-kinetic properties with biochemical and biophysical approaches, while [@B50] and [@B1] observed micron-sized Htt inclusions and their liquid- or solid-like properties mainly with fluorescent microscopy assisted by quantitative analysis. Considering the diverse sizes and conformations of mHtt species, thorough works with multiple mutually supportive approaches are needed to further explore the phase properties of mHtt assemblies. Nonetheless, these latest studies have shed new light to the understanding of the polymorphism of mHtt species at different scales.

###### 

Summary of mHtt phase behavior.

  **Htt fragments**     **System**                                **Phase behavior**                                                                                                                               **References**
  --------------------- ----------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------------
  mHtt-NTF-40Q          *In vitro*                                Concentration dependently forms separable M phase (soluble monomer), S phase (soluble aggregates) and F phase (insoluble fibrillar aggregates)   [@B53]
  mHtt~ex1~-25Q-EGFP    Budding yeast                             None                                                                                                                                             [@B50]
  mHtt~ex1~-25QP-EGFP   *In vitro* Budding yeast Mammalian cell   LLPS, liquid to solid transition LLPS LLPS                                                                                                       
  mHtt~ex1~-43Q-EGFP    Budding yeast                             LLPS, liquid to solid transition                                                                                                                 
  mHtt~ex1~-43QP-EGFP   Budding yeast Mammalian cell              LLPS, liquid to solid transition LLPS, liquid to solid transition                                                                                
  mHtt~ex1~-97Q-EGFP    Budding yeast                             LLPS, liquid to solid transition                                                                                                                 
  mHtt~ex1~-97QP-EGFP   Budding yeast Mammalian cell              LLPS, liquid to solid transition LLPS, liquid to solid transition                                                                                
  mHtt~ex1~-25QP-EGFP   Budding yeast                             None                                                                                                                                             [@B1]
  mHtt~ex1~-72QP-EGFP   Budding yeast                             Phase separated to gel-like inclusions                                                                                                           

Factors Affecting mHtt Phase Transition {#S3.SS2}
---------------------------------------

Diverse factors are known to affect mHtt aggregation; whether they can also modulate mHtt phase transition was also explored by in the studies discussed in the previous section.

[@B53] characterized the saturation concentrations of soluble mHtt-NTF for its S and F phases and found that the sequence flanking the mHtt polyQ region affects the phase boundaries. Specifically, the 17N-terminal amino acids of mHtt (N17) lower the fibrillar-phase saturation concentration *c*~F~, indicating N17 facilitates mHtt-NTF phase separation *in vitro*, while the proline-rich region downstream of polyQ sequence (i.e., P-rich region) increases *c*~F~, suggesting it lowers the driving force for mHtt-NTF phase separation. The authors also studied in depth how profilin, a small actin-binding protein, may contribute to the modulation of mHtt-NTF phase separation. They observed that profilin preferably binds to the soluble monomers and oligomers of mHtt-NTF, thereby destabilize mHtt-NTF aggregates. Moreover, computer simulation suggests profilin interacts with mHtt-NTF through a combined effect of specific binding with the P-rich region and auxiliary binding with the polyQ sequence. Interestingly, mHtt-NTF with longer polyQ (40Q vs. 30Q) showed higher affinity with profilin in protein binding assays.

[@B50] also looked at polyQ length and the P-rich region for their roles in mHtt phase transition. In both yeast and mammalian cells, mHtt~ex1~ with different length of polyQ (25, 43, and 97) can all form liquid-like assemblies, but a polyQ expansion (43 and 97) is required for solid-like assemblies' formation. *In vitro*, however, even mHtt~ex1~ with 25Q can also undergo liquid to solid transition. P-rich region assists the mHtt~ex1~ to form assemblies in yeast, whether this is also the case in mammalian cells is unclear. The authors also tested whether electrostatic interactions play a role in mHtt phase separation and found that even very high salt concentration (up to 1M) had little effect on mHtt-25QP droplet formation *in vitro*. In their yeast experiments, the authors also looked at the yeast prion \[RNQ+\] and found it not required for mHtt~ex1~ phase separation.

[@B1] checked phase transition of mHtt~ex1~ with different polyQ length (25Q and 72Q) as well. Consistent with previous reports ([@B33]; [@B40]) and Peskett et al.'s work, mHtt~ex1~-25Q did not form inclusions. Besides, Hsp104, a yeast disaggregase, is required for inclusion formation as reported before ([@B33]; [@B40]). Interestingly, [@B1] did not see mHtt~ex1~-72Q forming any liquid-like or solid-like assemblies in *rnq1*Δ strains.

In summary, several factors can affect mHtt phase transition. Expanded polyQ is required for mHtt phase transition in both studies with mHtt~ex1~-GFP under fluorescent microscopy. The effect of the flanking sequences, however, looks somewhat controversial. The P-rich region lowers the driving force for phase separation *in vitro* and facilitates profilin in suppressing mHtt~ex1~ aggregation ([@B53]), but promotes intracellular mHtt~ex1~ phase separation in yeast ([@B50]). One possible explanation for this discrepancy is, compared with the *in vitro* aggregation system, the intracellular milieu contains many more mHtt-interacting proteins potentially affecting mHtt phase separation. Profilin, Hsp104, and Rnq1 are some examples, although the exact mechanisms by which they modulate mHtt phase separation still requires further studies. It's worth mentioning that although [@B50] found the \[RNQ+\] prion is not required for mHtt~ex1~ phase separation, [@B1] reported yeast cells lacking the RNQ1 gene were unable to form mHtt assemblies. Because these two experiments were carried out in different yeast strains with different \[RNQ+\] prion-forming properties, it is thus still unclear whether the non-prion form of Rnq1 protein assists mHtt phase separation.

Besides the intrinsic and intracellular factors explored in the above-mentioned studies, there are also factors that may affect mHtt phase transition in intercellular manners. mHtt aggregates were first reported to have prion-like properties such as templated misfolding *in vitro* and intercellular propagation in co-cultured cells \[reviewed in [@B47]\]. Later studies reported that mHtt aggregates also underwent intercellular transfer in mouse brains and contribute to HD pathology phenotypes ([@B48]; [@B29]). A more recent work using a FRET-based mHtt aggregate seeding assay indicates a strong correlation between mHtt species' seeding activity and HD pathology progression ([@B7]). It is thus crucial to explore whether and how an mHtt aggregate "seed" obtained via intercellular transfer may affect the local mHtt phase transition. In addition, recent studies in Alzheimer's disease (AD) cells suggest that microglia are capable of uptake tau "seeds" but may promote their intercellular propagation via incomplete degradation ([@B60]). Whether similar mechanisms also contribute to mHtt aggregation intercellularly remain to be explored.

Htt Phase Transition and HD: Pathological Relevance {#S3.SS3}
---------------------------------------------------

Although the discovery of phase transition of mHtt may bring exciting new directions in HD research, a few key questions need to be answered to understand its pathological relevance.

First, it is crucial to know whether phase transition is a universal mechanism underlying mHtt aggregation in all cells, especially in neurons. Studies so far were carried out *in vitro*, in yeast cells and in HEK cells. It is critical to confirm the current findings in more relevant HD cell models such as neuronal cell lines or iPSC-derived neurons ([@B21]). Cell-type-specific difference of mHtt aggregation has been reported in mice HD models ([@B28]). Microglia from frontal cortex and striatum have much lower frequency of nuclear mHtt aggregation than neurons and other glia cells from the same brain areas, despite of similar mHtt expression levels. The still unclear mechanisms underlying the cell-type-specific mHtt aggregation might also affect mHtt phase transition.

Second, mHtt is known to form aggregates in both the cytoplasm and nucleus, which are of very different biomolecule environment. Moreover, it is proposed that cytosolic and nuclear mHtt aggregates contribute differently to toxicity ([@B30]). It is thus necessary to compare cytosolic and nuclear mHtt phase transition, if applicable, to understand their physiological consequences. For example, HD is known to manifest nucleolar dysfunction and impaired rDNA transcription ([@B36]). Very recently, Frottin et al. found that the nucleolar granular component (GC) also undergoes phase separation and can serve as a membrane-less protein quality control compartment to temporarily store denatured proteins and prevent them from irreversible aggregation ([@B18]). But the capacity of the nucleolus to buffer proteinaceous folding stress is limited. When overloaded, the GC liquid phase will go through a transition to solid phase and subsequently lead to nucleolar dysfunction. Whether intranuclear mHtt affect GC phase separation, for instance, by disrupting the process directly or by overwhelming its buffering capacity, will be a very interesting question worth testing.

Third, according to the reports so far, the expanded polyQ is required for mHtt to form solid-like assemblies but not for some liquid like assemblies. In other words, wild-type Htt (wtHtt) can also form liquid-like assemblies. Considering most HD patients are heterozygous that expresses a mixture of wtHtt and mHtt, it is closely relevant to study possible interactions between wtHtt and mHtt in their phase transition. The interaction between wtHtt and mHtt has been reported to affect disease progression and mHtt toxicity ([@B24]; [@B35]; [@B8]; [@B55]). Htt with wide-type polyQ length (25Q) was also found in mHtt (103Q) aggregates ([@B17]). Whether these reported interactions involve phase transition will be another interesting question to explore.

In summary, the discovery of phase transition of mHtt revealed a new mechanism involved in mHtt aggregation. Understanding the pathological relevance of different mHtt phases (e.g., the cytotoxicity of liquid phase and solid phase) and the factors that affect their transition, such as profilin that stabilize soluble mHtt phase and destabilize mHtt aggregates, will be crucial in identifying potential targets to interfere mHtt phase transition. Antagonizing the pathological mHtt phase transitions and correcting the normal phase transition could be a new strategy in treating the disease.

Future Perspectives {#S4}
===================

It's been almost three decades since the discovery of the causing gene of HD and the identity of aggregates found in patients. However, the mechanisms of mHtt aggregation and toxicity are still not fully understood. The discovery of the phase transition of mHtt added a new mechanism of mHtt aggregation and will help us to have a better understanding of the underlying molecular events. Considering that Htt with regular polyQ length can also go through LLPS, it is possible that de-regulated phase transition of mHtt also contribute to the pathology of the disease.

Moreover, accumulating evidence indicate that phase transition is used by the cell to regulate diverse intracellular biological processes such as autophagy ([@B61]; [@B20]) and protein quality control ([@B18]; [@B66]), both are compromised in HD. Can phase transition be a new mechanism that mHtt affect normal cellular "daily life"? In other words, is it possible that mHtt undermine essential cellular functions via disrupting their phase transition-mediated events? Furthermore, can the phase transition of mHtt interfere with phase transition of other biological macromolecules? Some hundreds of proteins were found in mHtt aggregates ([@B25]), could some of them be a result of mHtt-disrupted phase transition? Given the case that profilin affects the phase boundaries of mHtt, this possibility looks conceivable and is certainly worth testing, at least for mHtt-interacting proteins.

Although intracellular phase transition was confirmed not for long, it has already been reported to be involved in a number of diseases features protein aggregation, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) ([@B43]; [@B46]; [@B42]), AD ([@B3]; [@B64]). and HD (this review). Phase transition thus may serve as a new targetable process for treating these diseases ([@B63]). However, like the case of HD discussed in this review, this can only base on a thorough knowledge of phase separation in general and phase transition of the specific target protein.
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